8-K: Sanuwave Reports Record Q2 Revenue, Strong Growth

Sanuwave Health, Inc. announced its Q2 2025 financial results, reporting record revenue and significant growth in UltraMist system sales.

Summary

• Q2 2025 revenues reached $10.2 million, a 42% increase from $7.2 million in Q2 2024, marking the highest Q2 quarterly revenues in company history.
• Gross margin improved to 78.3% in Q2 2025, up from 73.2% in Q2 2024.
• GAAP Operating Income for Q2 2025 was $1.9 million, slightly down from $2.0 million in Q2 2024, impacted by $1.1 million in equity compensation costs.
• Net income for Q2 2025 was $1.1 million, compared to $6.6 million in Q2 2024, with the prior year benefiting from a non-recurring $5.3 million gain on extinguishment of debt.
• Adjusted EBITDA for Q2 2025 significantly increased to $3.4 million from $1.5 million in Q2 2024.
• The company sold 116 UltraMist systems in Q2 2025, an increase from 72 in Q2 2024 and 98 in Q1 2025.
• UltraMist consumables revenue grew by 37% to $6.4 million in Q2 2025, representing 99% of overall revenues.
• For the first six months of 2025, revenue grew 51% compared to the same period in 2024, with 214 UltraMist systems sold, exceeding full-year 2023 sales and an 86% increase year-over-year.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong revenue growth, improved gross margins, and a significant increase in Adjusted EBITDA. Management's optimistic outlook on sales expansion and future performance also contributes positively. However, the decline in GAAP net income (due to non-recurring items and stock compensation) and the substantial debt and stockholders' deficit temper the overall sentiment.

Positives

• Achieved highest Q2 quarterly revenues in company history at $10.2 million, a 42% increase year-over-year.
• Gross margin improved significantly to 78.3% in Q2 2025 from 73.2% in Q2 2024.
• Adjusted EBITDA more than doubled to $3.4 million in Q2 2025 from $1.5 million in Q2 2024.
• UltraMist system sales increased substantially to 116 units in Q2 2025, up from 72 units in Q2 2024.
• UltraMist consumables revenue grew 37% to $6.4 million, demonstrating strong recurring revenue.
• Achieved full national sales coverage by mid-July, a key operational milestone.
• First six months of 2025 saw 51% revenue growth and 86% increase in UltraMist system sales compared to the same period in 2024.

Negatives

• GAAP Operating Income slightly decreased to $1.9 million in Q2 2025 from $2.0 million in Q2 2024, partly due to $1.1 million in equity compensation costs.
• Net income significantly declined to $1.1 million in Q2 2025 from $6.6 million in Q2 2024, primarily because of a non-recurring $5.3 million gain on extinguishment of debt in the prior year.
• Reported a net loss of $4.621 million for the six months ended June 30, 2025.
• Carries substantial senior secured debt of $26.774 million and warrant liability of $12.018 million as of June 30, 2025.
• Total Stockholders Deficit increased to $(14.775) million as of June 30, 2025, from $(12.717) million at December 31, 2024.

Risks

• Future performance is subject to risks associated with regulatory oversight.
• Ability to manage capital resources may impact operating results.
• Competition in the market could affect financial condition and performance.
• Other factors detailed in periodic filings with the Securities and Exchange Commission may affect operating results, performance, and financial condition.

Future Outlook

The company forecasts Q3 2025 revenue of $12-$12.7 million and reiterates full year 2025 revenue guidance of $48-$50 million, representing a 47-53% increase over full year 2024. Management expects Q3 to be a period of 'max construction' for new sales and marketing practices, including the launch of its first concerted marketing program, aiming for 'breakout performance' in Q4 2025 and 2026.

Management Comments

• "We’re pleased to have put up strong results for Q2 and to have achieved 51% revenue growth in the first six months of 2025 vs the same period in 2024."
• "We sold 214 UltraMIST systems in the first six months of this year, more than we did in the full year of 2023 and an increase of 86% versus same period in 2024."
• "Q1 and Q2 have been spent building and reshaping our sales and commercial operations teams, and as of mid July, the Company achieved full national sales coverage for the first time in my tenure as CEO."
• "If Q1 and Q2 were the quarters of max disruption Q3 is expected to be the quarter of max construction as the Company builds up momentum around our new sales and marketing practices (including the launch of our first concerted marketing program) with an aim to set us up for breakout performance in Q4 2025 and 2026."
• "The energy at our sales and commercial operations national meeting a couple of weeks ago was palpable. I think we’re all looking forward to seeing what Sanuwave can become as it starts firing on all cylinders."

Industry Context

Sanuwave Health operates in the wound care sector, focusing on patented, non-invasive, and biological response-activating medical systems for tissue repair and regeneration. The company positions itself as a leading provider of next-generation FDA-approved wound care products, with its UltraMist system and consumables forming 99% of its revenue, indicating a strong specialization in its niche within the broader regenerative medicine market.

Comparison to Industry Standards

• No specific comparable companies, projects, or results were mentioned in the filing to allow for a direct assessment against global benchmarks.

Related Party Transactions

• Interest expense, related party is noted in the condensed consolidated statements of comprehensive income (loss), but specific transaction details are not provided in this filing.

Stakeholder Impact

• Shareholders: Potential for increased share value due to strong revenue growth and positive future outlook, but also potential for dilution given the significant warrant liability and ongoing capital needs.
• Employees: Expansion of sales and commercial operations teams indicates job growth and strategic investment in human capital.
• Customers: Continued availability and increased marketing of UltraMist products suggest improved access and support for wound care solutions.
• Creditors: The substantial senior secured debt indicates a significant financial obligation, which will be a focus for creditors.

Next Steps

• Conduct a business update via conference call on August 8, 2025.
• Continue building and reshaping sales and commercial operations teams.
• Launch the first concerted marketing program.
• Aim for breakout performance in Q4 2025 and 2026.

Key Dates

Recommendation

While Sanuwave Health demonstrates strong operational performance with impressive revenue growth and improved gross margins, the significant decline in GAAP net income (due to non-recurring items and stock compensation) and a substantial stockholders' deficit warrant caution. The company's reliance on debt and warrant financing, as indicated by the balance sheet, suggests potential future dilution or financial restructuring. The positive operational momentum and management's strategic initiatives are encouraging, but the underlying financial structure presents risks. A 'hold' recommendation allows investors to observe the execution of the sales and marketing strategies and the impact on GAAP profitability and debt management before making a more definitive investment decision.

Keywords

Sanuwave Health, SNWV, Q2 2025, financial results, wound care, UltraMist, medical devices, earnings, NASDAQ, regenerative medicine